[{"id":"a688087c-68be-4853-9780-49620057e35d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04517851","created_at":"2021-01-18T21:38:49.784Z","updated_at":"2025-02-25T15:26:29.899Z","phase":"Phase 2","brief_title":"Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis","source_id_and_acronym":"NCT04517851","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2 • IL1R1 • SLAMF7","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • IL1R1 • SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Empliciti (elotuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/10/2021","start_date":" 02/10/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-10"},{"id":"f9819aac-8e0f-47ec-b5ac-1e665026469c","acronym":"CARAMBA-1","url":"https://clinicaltrials.gov/study/NCT04499339","created_at":"2022-01-21T23:05:20.797Z","updated_at":"2024-07-02T16:35:07.458Z","phase":"Phase 1/2","brief_title":"A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma","source_id_and_acronym":"NCT04499339 - CARAMBA-1","lead_sponsor":"Wuerzburg University Hospital","biomarkers":" SLAMF7","pipe":"","alterations":" ","tags":["SLAMF7"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-25"},{"id":"f1cfe322-7c0f-4270-b499-e5b443eefa43","acronym":"CARLOTTA01","url":"https://clinicaltrials.gov/study/NCT05836896","created_at":"2023-05-01T14:03:57.086Z","updated_at":"2024-07-02T16:35:18.546Z","phase":"Phase 1","brief_title":"A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies","source_id_and_acronym":"NCT05836896 - CARLOTTA01","lead_sponsor":"Technische Universität Dresden","biomarkers":" CD31 • SLAMF7","pipe":" | ","alterations":" CD38 positive","tags":["CD31 • SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDC-CAR-BCMA001"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/15/2024","start_date":" 02/15/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-20"},{"id":"6b7343bd-05b1-474c-8d36-fe39eab91743","acronym":"MM FPBMC","url":"https://clinicaltrials.gov/study/NCT04864522","created_at":"2021-04-29T12:55:37.907Z","updated_at":"2024-07-02T16:35:28.423Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT04864522 - MM FPBMC","lead_sponsor":"University of Virginia","biomarkers":" SLAMF7","pipe":"","alterations":" ","tags":["SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SLAMF7 FPBMC"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-11-21"},{"id":"9e72d219-f74b-4c5d-ba34-f05984c3935d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03958656","created_at":"2021-09-09T17:53:47.480Z","updated_at":"2024-07-02T16:36:24.633Z","phase":"Phase 1","brief_title":"T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma","source_id_and_acronym":"NCT03958656","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SLAMF7","pipe":"","alterations":" ","tags":["SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Anti-SLAMF7 CAR T cells • rimiducid (AP1903)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/13/2019","start_date":" 06/13/2019","primary_txt":" Primary completion: 10/13/2020","primary_completion_date":" 10/13/2020","study_txt":" Completion: 01/19/2021","study_completion_date":" 01/19/2021","last_update_posted":"2021-09-09"}]